Dermatological adverse drug reactions to tyrosine kinase inhibitors: a narrative review

Das, Anupam; Sil, Abheek; Khan, Ismat; Bandyopadhyay, Debabrata

doi:10.1093/ced/llad070

Cited by 5 publications

(3 citation statements)

References 89 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, hypopigmentation was only reported once among patients receiving non‐imatinib TKIs in our review 16 . While hypopigmentation is a well‐known adverse effect of imatinib, it has also been seen with other TKIs not used for CML, such as cabozantinib and pazopanib 17 . Additionally, alopecia was only reported in two patients, both of whom received imatinib.…”

Section: Discussionmentioning

confidence: 77%

See 1 more Smart Citation

Skin reactions to tyrosine kinase inhibitors in pediatric patients with chronic myeloid leukemia

Toker,

Jaller,

Delbourgo Patton

et al. 2023

Pediatric Dermatology

View full text Add to dashboard Cite

Cutaneous adverse events are commonly reported in adult patients with chronic myeloid leukemia (CML) receiving tyrosine kinase inhibitors (TKIs); however, little is known about the cutaneous reactions in children receiving TKIs for CML. As pediatric patients may require lifelong TKI therapy, it is essential to understand the wide range of potential cutaneous toxicities. We examined all case studies, cohort studies, and clinical trials in PubMed/MEDLINE and Embase that reported cutaneous reactions to first‐, second‐, and third‐generation TKIs in children 18 years or younger with CML. This review article focuses on the TKI drug types and doses, patient demographic characteristics, features of skin reactions, and clinical outcomes.

show abstract

Section: Discussionmentioning

confidence: 77%

“…TKIs not used for CML, such as cabozantinib and pazopanib. 17 Additionally, alopecia was only reported in two patients, both of whom received imatinib. Interestingly, our review's most frequently reported skin reaction was unspecified rash (67%, 133/199).…”

Section: Discussionmentioning

confidence: 99%

Skin reactions to tyrosine kinase inhibitors in pediatric patients with chronic myeloid leukemia

Toker,

Jaller,

Delbourgo Patton

et al. 2023

Pediatric Dermatology

View full text Add to dashboard Cite

show abstract

“…. Nevertheless, drug resistance and frequent relapse and associated adverse effects, including cardiovascular as major along with pulmonary and gastrointestinal disturbances, neuropathies, stomatitis, nasal bleeding, retinopathy, edema, dry skin, pruritis, pancreatitis, and hepatitis, remained as few to name as major bottlenecks with the advanced TKI application for Ph+ leukemia complete remission. − Currently, ponatinib is the only drug that remains the most potent against most of TKI’s resistant forms.…”

Section: Introductionmentioning

confidence: 99%

Titania–Graphene Oxide Nanocomposite-Based Philadelphia-Positive Leukemia Therapy

Batool,

Qazi,

Mudassir

et al. 2024

ACS Appl. Bio Mater.

View full text Add to dashboard Cite

Philadelphia-positive (Ph+) leukemia is a type of blood cancer also known as acute lymphoblastic leukemia (ALL), affecting 20−30% of adults diagnosed worldwide and having an engraved prognosis as compared to other types of leukemia. The current treatment regimens mainly rely on tyrosine kinase inhibitors (TKIs) and bone marrow transplants. To date, several generations of TKIs have been developed due to associated resistance and frequent relapse, with cardiovascular system anomalies being the most devastating complication. Nanotechnology has the potential to address these limitations by the targeted drug delivery and controlled release of TKIs. This study focused on the titanium dioxide (TiO 2 ) and graphene oxide (GO) nanocomposite employment to load nilotinib and ponatinib TKIs for therapy of Ph+ leukemia cell line (K562) and Ba/F3 cells engineered to express BCR-ABL oncogene. Meanwhile, after treatment, the oncogene expressing fibroblast cells (Rat-1 P185) were evaluated for their colony formation ability under 3D conditions. To validate the nanocomposite formation, the TiO 2 −GO nanocomposites were characterized by scanning electron microscope, DLS, XRD, FTIR, zeta potential, EDX, and element mapping. The TKI-loaded TiO 2 −GO was not inferior to the free drugs after evaluating their effects by a cell viability assay (XTT), apoptosis induction, and colony formation inhibition. The cell signaling pathways of the mammalian target of rapamycin (mTOR), signal transducers and activators of transcription 5 (STAT5), and extracellular signal-regulated kinase (Erk1/2) were also investigated by Western blot. These signaling pathways were significantly downregulated in the TKI-loaded TiO 2 −GO-treated groups. Based on the findings above, we can conclude that TiO 2 −GO exhibited excellent drug delivery potential that can be used for Ph+ leukemia therapy in the future, subject to further investigations.

show abstract

The spectrum of cutaneous toxicities related to novel genitourinary cancer therapies

Daher,

Ruplin,

Gupta

et al. 2024

Critical Reviews in Oncology/Hematology

View full text Add to dashboard Cite

Dermatological adverse drug reactions to tyrosine kinase inhibitors: a narrative review

Cited by 5 publications

References 89 publications

Skin reactions to tyrosine kinase inhibitors in pediatric patients with chronic myeloid leukemia

Skin reactions to tyrosine kinase inhibitors in pediatric patients with chronic myeloid leukemia

Titania–Graphene Oxide Nanocomposite-Based Philadelphia-Positive Leukemia Therapy

The spectrum of cutaneous toxicities related to novel genitourinary cancer therapies

Contact Info

Product

Resources

About